A phase 2, multicenter, placebo-controlled study of single-dose squaric acid dibutyl ester to reduce frequency of outbreaks in patients with recurrent herpes labialis

J Am Acad Dermatol. 2020 Dec;83(6):1807-1809. doi: 10.1016/j.jaad.2020.04.021. Epub 2020 Apr 11.

Authors

Anne Lynn S Chang¹, Golara Honari¹, Linna Guan¹, Ludan Zhao¹, Maria Alora Palli², Thomas D Horn³, Arkadiusz Z Dudek⁴, Hugh McTavish⁵

Affiliations

¹ Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Squarex, LLC, Pine Springs, Minnesota.
⁴ Squarex, LLC, Pine Springs, Minnesota.
⁵ Squarex, LLC, Pine Springs, Minnesota. Electronic address: hmctavish@squarex-pharma.com.

PMID: 32289388
DOI: 10.1016/j.jaad.2020.04.021

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Adjuvants, Immunologic / adverse effects
Administration, Topical
Cyclobutanes / administration & dosage*
Cyclobutanes / adverse effects
Double-Blind Method
Drug Administration Schedule
Herpes Labialis / diagnosis
Herpes Labialis / drug therapy*
Herpes Labialis / immunology
Herpes Labialis / virology
Herpesvirus 1, Human / immunology
Humans
Placebos / administration & dosage
Placebos / adverse effects
Recurrence
Secondary Prevention / methods*
Severity of Illness Index
Symptom Flare Up*
Treatment Outcome

Substances

Adjuvants, Immunologic
Cyclobutanes
Placebos
squaric acid dibutyl ester